The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Merck gained Keytruda in the 2009 acquisition of Schering-Plough Corp for $41B. Bex may be an even more effective drug than Keytruda.
I also hope that it will come in one quick sale because otherwise it will be very difficult to decide when to sell. My poker might not be able to handle waiting to get to £100 the slow way. So much at stake.
My crystal ball says that Faron's market cap will reach £6B. In this case, the share price would be £100. And if someone happened to own 10000 shares they would be worth £1M. And then I'll sell them ;)
Faron says "88 billion USD (2027) Predicted target market for bexmarilimab" (slide 3)
https://www.faron.com/sites/default/files/2022-06/Investment%20Case%20verification%20deck%20CLEAN%2013.10.2022.pptx
Not bad if it comes true...
@Luckenbach, four Doctors in Markku's family are:
Markku Jalkanen
Sirpa Jalkanen (wife)
Juho Jalkanen (son)
Maija Hollmén (daughter)
They all work at either Faron or the Hollmen Lab (part of University of Turku), which does research for Faron.
Not everyone on DCR-group (30-40% of patients) survive. Only 83% of them. Therefore your probability to be alive after 6 month is 25-33% if you belong on DCR-group and 28% if you belong on non-DCR-group which doesn't get any help of Bex. So what's the difference of your alive probability? How would you calculated this?
Bex has impact to 30-40% patients (DCR) which 83% are alive after six month. 83% of 30% is 25% and 40% of 83% is 33%. And 28% of patients not affected by Bex (non-DCR) are also alive after six months. So is there any benefit (25-33% versus 28%) after all? Or is there something what I don't understand now?
Nasdaq Helsinki at moment: 3,65 € / +17,74 %
Canadian researchers participate in trial to see if interferon is effective early treatment for COVID-19:
https://www.theglobeandmail.com/amp/canada/article-chilean-covid-19-trial-promises-definitive-test-for-canadian-champion/?utm_medium=Referrer:%20Social%20Network%20%2F%20Media&utm_campaign=Shared%20Web%20Article%20Links&__twitter_impression=true
Ah, this chat does not support links?
Go to twitter and find Hollmén lab. There is tweet by Dr. Maija Hollmén (Faron's CEO daughter).
Hollmén lab
@maijahollmen
Exciting work from Mantovani and colleagues: Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis | Journal of Experimental Medicine | Rockefeller University Press https://rupress.org/jem/article/217/11/e20191847/152014/Macrophage-morphology-correlates-with-single-cell#.XzZOR4auOz0.twitter
Translate tweet
11.42 am. · 14. aug. 2020·Twitter Web App
webby
@iyoriniygo521
14. aug.
Reply
@maijahollmen
Does this relate directly or indirectly to Clevegen
Hollmén lab
@maijahollmen
14. aug.
Our data show that Clevegen inhibits LXR and PPAR pathways in monocytes of MATINS trial patients
webby
@iyoriniygo521
24. aug.
Reply
@maijahollmen
Maija...is there an update for Clevegen due soon
Hollmén lab
@maijahollmen
24. aug.
I hope so. We have a manuscript under review.
webby
@iyoriniygo521
24. aug.
Reply
@iyoriniygo521
And
@maijahollmen
That's great...are the results looking promising
Hollmén lab
@maijahollmen
25. aug.
Yes they are [smile face emoji]
Good news from Clevegen by Dr. Maija Hollmén (Faron's CEO daughter)! She tweets:
https://twitter.com/maijahollmen/status/1294192754675929088